



**Gary J. Sternberg, MD, MBA,
Appointed Chief Business Officer of Fovea Pharmaceuticals**

Paris, France – September 28, 2006 – Fovea Pharmaceuticals SA, an integrated biopharmaceutical company specialized in the discovery, development and commercialization of novel drugs for the treatment of ocular diseases, with a special focus on retinal pathologies, announced today the appointment of Dr Gary Jay Sternberg, MD, MBA as Senior Vice-President and Chief Business Officer.

Gary J. Sternberg joins Dr. Barrett Katz, Executive Vice President and Chief Medical Officer, at the New York branch of Fovea Pharmaceuticals. He will focus on Fovea's licensing and product acquisition strategy and will also assist Fovea to develop and market therapies directed at diseases in the ophthalmic space.

Dr. Sternberg has accumulated over 12 years of experience in licensing, business development, clinical research and medical practice. He held the position of Vice President, Alliance Management and Business Development at Eyetech Pharmaceuticals (recently acquired by OSI) prior to joining Fovea. As such, he was lead negotiator at Eyetech on all key licensing deals over the last 3 years. Prior to this, he worked for Bristol-Myers Squibb (BMS) and DuPont Pharmaceuticals Company in significant business development roles. He started his career as an ophthalmologist and trained at New York's Mount Sinai Medical Center. Dr. Sternberg subsequently worked in private clinical practice, where he concentrated on the treatment of general ophthalmology, cornea and external ocular diseases.

Bernard Gilly, Chairman and CEO of Fovea, stated: "We are very happy to welcome Gary onto our team today. His in-depth knowledge of licensing and acquisitions in ophthalmology, combined with his ophthalmic medical experience, will effectively complement the clinical network and expertise developed by Pr. Jose Sahel, co-founder of Fovea, and by Dr. Barrett Katz, who recently joined Fovea and with whom Gary has already worked in close cooperation. Gary's skills and competence will be key for adding to Fovea's product pipeline and in helping advance these products from clinical trials to market."

Gary Sternberg added: "I am very pleased to join the Fovea Pharmaceuticals team, with whom I already had many connections. I am also excited to play an active part in helping Fovea build a successful drug development and commercial company, with the chance to bring novel eye drugs to patients in need."

About Fovea Pharmaceuticals SA

Fovea Pharmaceuticals SA (Fovea) is a Paris-based biopharmaceutical company specialized in development and commercialization of innovative drugs for the treatment of ocular diseases (dry eye, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy), with a special focus on retinal pathologies. Created in May 2005, Fovea's highly experienced board and management team includes Bernard Gilly, Chairman and CEO, Professor José-Alain Sahel, Chief Scientific Advisor, Pierre Bélichard, COO and Barrett Katz, Executive Vice-President and Chief Medical Officer, based in New York City.

Fovea has been funded by five leading European investors led by Sofinnova Partners and including Abingworth Management, The Wellcome Trust, GIMV and Crédit Agricole Private Equity. Fovea raised a Series A financing round of \$25 million (€20.5million) in November 2005 and has initiated last January 31st a collaboration with CombinatoRx to develop novel ophthalmic therapeutics built from synergistic drug combinations. For further information, please visit the Fovea website at www.fovea-pharma.com

Fovea Pharmaceuticals SA
Catherine Viard
Administrative & Finance Manager
+33144164243
info@fovea-pharma.com
Press Contact : EuroRSCG C&O
Marie Carole de Groc
+33158479507
marie-carole.de-groc@eurorscg.fr